Finally, Migraine-Specific Preventive Therapy Is on the Horizon

Calcitonin gene-related peptide (CGRP) has been a long-standing therapeutic target of interest in migraine. Small-molecule CGRP receptor antagonists demonstrated effectiveness for the treatment of acute migraine attacks, but hepatotoxicity limited their development. In this phase II, randomized, placebo-controlled, manufacturer-funded study, researchers randomized 218 adult migraineurs: 108 to LY2951742 — a fully humanized monoclonal antibody to CGRP — and 110 to placebo. At baseline, participants had approximately 7 migraine days per 28-day period. The intervention consisted of a subcutaneous injection of either 150 mg of LY2951742 or masked placebo (saline) every 2 weeks for 12 weeks, followed by an additional 12-week monitoring period fo…